Ketogenic Diet for Health & Longevity - Quick Reference Sheet

Ketogenic Diet for Health & Longevity

Created on 09/01/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Cutting carbohydrate enough to burn fat-derived fuels reliably lowers body fat and blood sugar, calms seizure disorders and lifts low mood. It also raises the cholesterol-carrying particles most tied to heart disease. Muscle can be lost unless protein and training are protected, replacement foods matter more than the restriction, and no study has measured whether anyone lives longer. (Full Review)

Protocol

Standard ketogenic composition
Under 50 g carbohydrate daily
Often 20–30 g net; protein 1.2–2.0 g per kg, remainder fat
Best time of day
Carbohydrate constrained at the evening meal
Insulin sensitivity is lowest then; targeted carbohydrate placed before or immediately after training
Single versus split intake
Two to three meals
Compatible with time-restricted eating; protein split across meals better supports muscle retention
Time to effect
Weight and cholesterol
8–12 weeks
Changes need this long to read reliably
Blood sugar and triglycerides
2–4 weeks
The metabolic response window
Measurable ketosis
2–4 days
Electrolyte symptoms peak in week one and resolve by week three

Benefits

Contraindications
  • Inherited fatty-acid oxidation, carnitine-transport, pyruvate-carboxylase or porphyria disorders
  • Pregnancy and breastfeeding
  • Type 1 diabetes without specialist supervision and continuous ketone monitoring
  • Concurrent SGLT2 inhibitor therapy that will not be discontinued
  • Pancreatitis history, or severe hypertriglyceridaemia above 11.3 mmol/L (1,000 mg/dL)
  • Chronic kidney disease stage 4–5 (below 30 mL/min/1.73 m²)
  • Liver failure, Child-Pugh Class B or C
  • Active eating disorder, or body mass index below 18.5 kg/m²
Key Interactions
  • Insulin and sulfonylureas (glipizide, glyburide, glimepiride)
  • Antihypertensives and diuretics (hydrochlorothiazide, furosemide, lisinopril)
  • Warfarin
  • Lithium
  • Carbonic anhydrase inhibitors (topiramate, zonisamide, acetazolamide)
  • Over-the-counter medications (sugar-based syrups, chewable antacids, effervescent tablets, non-steroidal anti-inflammatory drugs)
  • Supplement interactions (exogenous ketone salts and esters, medium-chain triglyceride oil, creatine, caffeine)
  • Supplements with additive glucose-lowering effects (berberine, chromium picolinate, alpha-lipoic acid, cinnamon extract, inositol)
  • GLP-1 receptor agonists (semaglutide)
  • Extended fasting

Risk & Side Effects

  • High: LDL cholesterol and apolipoprotein B elevation; gastrointestinal disturbance
  • Medium: Kidney stone formation; loss of lean mass; reduced bone mineral density; cardiovascular events and mortality with animal-based carbohydrate restriction; reduced circulating triiodothyronine
  • Low: Coronary plaque progression in lean hyper-responders; early adaptation symptoms; reduced resting testosterone with high-protein carbohydrate restriction; micronutrient inadequacy
  • Speculative: Gut microbiome shift away from fibre-fermenting bacteria; accelerated cellular senescence

Monitoring

Marker Target Why
Apolipoprotein B < 80 mg/dL; < 60 if plaque present Counts the atherogenic particles this diet is most likely to raise
LDL cholesterol < 100 mg/dL, and no more than a 30% rise from baseline Tracks the high-quality-evidence adverse effect
Lipoprotein(a) < 30 mg/dL (< 75 nmol/L) Genetically fixed particle that multiplies the harm of any cholesterol rise
Triglycerides 50–90 mg/dL Fastest-improving marker; confirms the diet is working metabolically
HDL cholesterol > 55 mg/dL men, > 65 mg/dL women Rises predictably; a flat response suggests poor adherence
HbA1c 4.8–5.4% Confirms the glycaemic benefit and detects loss of control
Fasting insulin 2–5 µIU/mL The earliest marker of the diet's core metabolic effect
β-Hydroxybutyrate (blood) 0.5–2.0 mmol/L metabolic; 2–4 mmol/L epilepsy Confirms ketosis and prevents chasing meaningless higher numbers
Magnesium (RBC) 5.0–6.5 mg/dL Depleted by ketogenic diuresis; drives cramps and insomnia
Sodium and potassium Sodium 138–142 mmol/L; potassium 4.0–4.5 mmol/L Detects the losses behind adaptation symptoms and fainting
Uric acid 3.5–5.5 mg/dL Rises early and drives the uric-acid stones that predominate on this diet
Free T3 and TSH Free T3 3.0–4.0 pg/mL; TSH 0.5–2.0 mIU/L Detects the active-thyroid-hormone fall this diet produces
eGFR and creatinine eGFR > 90 mL/min/1.73 m² Kidney function guards the stone and dehydration risks
25-hydroxyvitamin D 40–60 ng/mL Underpins the calcium handling that protects bone during ketosis
Body composition (lean mass) No established target; track change from the individual's own baseline Lean-mass loss is the risk most directly opposed to a longevity goal
Coronary artery calcium score 0 Agatston units Turns a lipid change into a personal plaque figure

Cadence: Baseline testing before starting; electrolytes and magnesium at 2 weeks; full lipid and metabolic panel at 8 weeks and 6 months, then every 6–12 months while the diet continues; body composition at 3 and 6 months; bone density every 24 months above age 50 or with a fracture history.

Qualitative Assessment

  • Energy stability through the afternoon, and whether the mid-afternoon slump disappears
  • Mental clarity and word-finding, which typically dip in week one and then improve
  • Sleep onset latency and night waking, the most common early complaint
  • Hunger between meals, and whether food preoccupation falls or rises
  • Training performance, separating endurance sessions from sprint and heavy-lifting work
  • Digestive regularity, the leading reason people abandon the diet after adaptation
  • Menstrual regularity in women, an early signal that restriction is too deep